Key result
Gene therapy has the potential to treat acquired polygenic diseases such as congestive heart failure due to advances in understanding its molecular basis and efficient gene transfer technology.
Gene therapy is emerging as a potential therapeutic approach for acquired polygenic diseases such as congestive heart failure.
Answers are grounded in this paper and cite their sources.
May inform future heart failure strategies; leaves open clinical translation from molecular advances.
Heart failure is a major cause of morbidity and mortality in contemporary societies. Although progress in conventional treatment modalities is making steady and incremental gains to reduce this disease burden, there remains a need to explore new and potentially therapeutic approaches. Gene therapy, for example, was initially envisioned as a treatment strategy for inherited monogenic disorders. It is now apparent that gene therapy has broader potential that also includes acquired polygenic diseases, such as heart failure. Advances in the understanding of the molecular basis of conditions such as these, together with the evolution of increasingly efficient gene transfer technology, has placed congestive heart failure within reach of gene-based therapy.
No takes yet. Share an insight, caveat, or question.
Ly et al. (2007) conducted a review in Heart failure. Gene therapy was evaluated. Gene therapy has the potential to treat acquired polygenic diseases such as congestive heart failure due to advances in understanding its molecular basis and efficient gene transfer technology.
Synapse has enriched 10 related papers. Consider them for comparative context: